The INTERLINK-1 trial was testing monalizumab – an NKG2A receptor inhibitor – in combination with EGFR-targeting antibody cetuximab in patients with recurrent or metastatic squamous cell ...

Giant cell arteritis (GCA) can be successfully treated with the oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq), ...

The firm will track the activity of the triplet broadly in AML patients, including in those with FLT3, NRAS, and TP53 mutations.

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...